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In a search of peripheral factors that could be responsible for the discrepancy in susceptibility to EAE in Albino Oxford (AO)
and Dark Agouti (DA) rats, we estimated the expression of metallothioneins I/II (MT), heat shock protein-gp96, interleukin (IL)-
6, and transforming growth factor (TGF)-𝛽 in the livers of these animals. Rats were immunized with bovine brain homogenate
(BBH) emulsified in complete Freund adjuvant (CFA) or only with CFA. Western blot and immunohistochemical analyses were
done on day 12 after the immunization, as well as in intact rats. The data have shown that during the first attack of EAE only the
EAE prone-DA rats markedly upregulated the hepatic MTs, gp96, IL-6, and TGF-𝛽. In contrast, AO rats had a significantly higher
expression of MT I/II, IL-6, and TGF-𝛽 in intact liver (𝑃 < 0, 001), suggesting that the greater constitutive expression of these
proteins contributed to the resistance of EAE. Besides, since previously we found that AO rats reacted on immunization by an early
upregulation of TGF-𝛽 on several hepatic structures (vascular endothelium, Kupffer cells, and hepatocytes), the data suggest that
the specific hepatic microenvironment might contribute also to the faster recovery of these rats from EAE.
1. Introduction
Multiple sclerosis (MS) is a heterogeneous disease in
which different mechanisms, such as an autoimmune attack,
inflammation, neurodegeneration, and intoxication, induce
demyelination, loss of oligodendrocyte and neurons, and
axonal injuries.The triggering event is usually the invasion of
peripherally activated myelin-specific Th1 and Th17 immune
cells in CNS, where they interact with antigen presenting
cells (APC) and microglial cells that drive the inflammatory
cascade leading to tissue damage and an amplification of
the initial immune reaction [1–3]. Underlying mechanisms
include, therefore, the breakdown of tolerance to autoanti-
gens, as well as the activation of cascades of cellular and
molecular events that contribute to initiation of the injury
or infection, such as the production of proinflammatory
cytokines, chemokines, and cell adhesion molecules as well
as the release of new collateral factors, such as damage-
and pathogen-associated molecular patterns (DAMPs and
PAMPs) that may potentiate the injury [4]. The outcome
depends also on the activation of local and systemic cyto-
protective and anti-inflammatory mechanisms, as well as on
the interplay between the pathogenic and regulatory T (Treg)
cells subpopulations that modulate the autoimmune attack.
The pathogenesis is multifactorial and dependent also on
the interrelationship between the neuroendocrine and the
immune system [5, 6], as well as on the presence of genes that
determine both the immune functions and the target organ
susceptibility for autoimmune disease [7].
Regarding the genetic background of EAE, a large num-
ber of information was obtained also in DA and AO rats’
strains, which have different susceptibilities to EAE [8–11].
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Thus, the discrepancy was found in the numbers of
immune cells that immigrate in the CNS, in production of IL-
2, interferon (IFN)-gamma, and interleukin (IL)-17 as well in
the secretion of IL-6, TGF-beta, and IL-10 within the CNS
or in draining lymph node cells. Contributing to this field
we have recently shown that these rat strains differ also in
the activation pattern of metallothioneins I/II [12], which
within themammalian CNS perform essential cytoprotective
functions, owing to their metal binding, antioxidative, anti-
apoptotic, and growth-regulatory activities [13–16]. In these
data [12], we have shown that constitutive and induced MT
I+II gene expression in EAE-resistant and EAE-prone rats
is different both in the organs that were damaged by the
autoimmune attack (hippocampus and cerebellum) as well as
in the liver, pointing to the high involvement of the central
and peripheral MTs-related mechanisms in the induction of
EAE. Besides, since in AO rats, early after immunization with
encephalitogen (on the seventh postimmunization day), we
found a marked upregulation of TGF-beta immunoreactivity
on several hepatic structures, we hypothesized that immuno-
suppressive environment in the liver probably contributed
also to the induction of resistance toward EAE [12].
In an attempt to enlarge these data, inDA andAO rats, we
made a quantitative analysis of hepatic expression of MT-I/II
proteins and two hepatic cytokines (IL-6 and TGF-𝛽), which
participate in acute phase reaction and in the creation of
the specific hepatic cytokine microenvironment that governs
the local balance between tolerance and immunity [17].
Moreover, owing to emerging evidence indicating that critical
regulators of cell stress response in neurological diseases [18]
as well as in the immune response [19–21] are the heat shock
proteins (HSPs), in DA and AO rats we estimated also the
hepatic expression of endoplasmic reticulum (ER) resident
HSP-gp96, which according to our own data might have the
essential function in the pathogenesis of chronic relapsing
EAE in DA rats [22].
The data have shown that only EAE-prone DA rats
significantly upregulated the hepatic MTs, gp96, IL-6, and
TGF-𝛽 during the appearance of first clinical symptoms, as
well as that AO rats have significantly higher MT I+II, IL-6,
and TGF-𝛽 expression in intact liver, suggesting that a high
constitutive expression of these proteins might contribute to
the resistance of EAE.
2. Materials and Methods
2.1. Experimental Animals. For the experiments male, Dark
Agouti (DA), and Albino Oxford (AO) rats were used, aged
2-3 months.They were bred and maintained according to the
guide for Institutional Animal Care and used with approval
of the Local Ethical Committee.
2.2. EAE Induction. Immunization was performed by bovine
brain white matter homogenate emulsion (BBH) in the
complete Freund’s adjuvant (CFA) (Sigma, St. Louis, MO,
USA), as we previously described [22–24]. Each animal
received 2 × 0.1mL of the emulsion, which was injected
subcutaneously, in each hind footpad. Control group was
injected with the same dose of CFA. Animals were sacrificed
on the 12th day after immunization with appearance of heavy
clinical symptoms of EAE that involve hind legs paralysiswith
incontinence. The severity of disease was clinically assessed
according to the following criteria: 0: no symptoms; 1: faccid
paralysis of tail; 2: hind legs paresis; 3: hind legs paralysis with
incontinence, and 4: death of animal.
2.3. Antibodies and Reagents. Mouse monoclonal antibody
to MT I/II (clone E9) was obtained from Dako Cytomation,
USA, and diluted 1 : 250 for WB and 1 : 50 for IHC-P. Mon-
oclonal Rat IgG2a antibody to Grp94/gp96 (clone 9G10) was
obtained fromStressgen, Canada, and used in dilution 1 : 1500
for WB and 1 : 100 for IHC-P. Mouse anti-rat antibody to IL-
6 was obtained from R&D systems, Abingdon, UK, and used
in dilution 1 : 200. Rabbit polyclonal IgG antibody to TGF-
𝛽 1 (1 : 600 for WB and 1 : 100 for IHC-P) was obtained from
Abcam, Cambridge, UK. Horse reddish peroxidase (HRP)-
goat anti-mouse IgG and HRP-goat anti-rat antibodies were
obtained from Jackson ImmunoResearch Laboratories, Inc.,
USA. HRP-goat anti-rabbit conjugated antibody, ECL Prime
Western Blotting Detection Reagent, andHybond ECL nitro-
cellulose membrane were obtained from GE Healthcare,
Uppsala, Sweden. Al HRP secondary antibodies were used
in dilution 1 : 10 000. Goat anti-mouse 𝛽-actin antibody was
obtained fromSantaCruzBiotechnology, Inc., USA, and used
in dilution 1 : 2000.
2.4. Western Blot Analyses. Equal amounts of frozen liver
tissues were homogenized and lysed in radioimmunoprecip-
itation assay (RIPA) buffer containing 25mM Tris-HCl pH
7.6, 300mM NaCl, 1% NP40, 1% sodium deoxycholate, 0.1%
SDS, 2mM PMSF, and complete protease inhibitor cocktail
tablets obtained from Roche, Mannheim, Germany. Proteins
were separated by 13% sodium dodecyl sulfate polyacry-
lamide gel electrophoresis (SDS-PAGE), under nonreduc-
ing conditions and then transferred onto a nitrocellulose
membrane (GE Healthcare, Uppsala, Sweden). Membranes
were then blocked with 1% blocking reagent (Roche Diag-
nostics GmbH) in tris-buffered saline with 0.5% Tween-
20 (TBST) and then incubated with different primary Abs,
followed by incubation with species specific HRP-conjugated
secondary antibodies. The 𝛽-actin was used as a control
of protein loading. Membranes were washed three times
with TBS buffer, incubated with Amersham ECL Prime
(GE Healthcare, Uppsala, Sweden), and scanned with Kodak
Image Station 440CF (Kodak, New Haven, CT, USA). The
intensity of the bands was quantified using ImageJ software
(http://rsb.info.nih.gov/ij/). To determine the relative expres-
sion of analyzed proteins in liver tissue of immunized animals
and animals treated only with CFA, the band density of each
liver sample was compared with the band intensity obtained
from liver tissue of intact animals after normalization to
an internal control (𝛽-actin). The analyses were made in
tissue samples made as a pool from 3 rats in three separate
experiments.
Clinical and Developmental Immunology 3
2.5. Tissue Preparation for Paraffin Slices. Liver were rapidly
removed and fixed in 10% buffered formalin solution during
24 h. Tissue was then embedded in paraffin wax and sections
were cut at 4 𝜇m using HM 340E microtome (Microtom,
Germany). Heat induced epitope retrieval was done prior to
staining procedure by heating tissue slides in boiled citrate
buffer pH 6.0 four times, each 5 minutes, using a microwave
steamer.
2.6. Immunohistochemistry. Immunohistochemical studies
were performed on paraffin embedded liver tissue slides
using DAKO EnVision + System, Peroxidase (DAB) kit
according to the manufacturer’s instructions (DAKO Corpo-
ration, USA). Briefly, slides were incubated with peroxidase
block to eliminate endogenous peroxidase activity. After
washing, antibodies were added to tissue samples and incu-
bated overnight at 4∘C in a humid environment, followed
by 45min incubation with peroxidase labeled polymer con-
jugated to goat anti-mouse or anti-rabbit immunoglobulins
containing carrier protein linked to Fc fragments to pre-
vent nonspecific binding. The immunoreaction product was
visualized by adding substrate-chromogen (DAB) solution.
Tissues were counterstained with hematoxylin, dehydrated
trough graded ethanols, mounted using Entelan (Sigma-
Aldrich, Germany), and examined with Olympus BX51
microscope (Olympus, Tokyo, Japan). The specificity of the
reaction was confirmed by substitution of primary anti-
bodies with isotype matched irrelevant immunoglobulins,
used under the same conditions and dilutions as primary
antibodies.
2.7. Statistical Analysis. Data were expressed as mean ± SE.
Differences between groups were assessed by Friedman one-
way analysis of variance (ANOVA), by Mann-Whitney𝑈 test
and by two tailed Student’s 𝑡-test.The level of significance was
set at 𝑃 < 0.05.
3. Results
As we previously described, the AO rats after immunization
with BBH+CFA did not exhibit any clinical symptom of
disease, in contrast to genetically susceptible DA rats, which
develop a typical chronic-relapsing form of EAE (CR-EAE).
In this study, animals from both groups were sacrified on day
12 after the immunization, that is, at time of the appearance of
first attack of disease in DA rats. Protein content of MT I/II,
gp96 and cytokines was analyzed in hepatic tissue samples
obtained from immunizedDAandAOrats (𝑁 = 9), from rats
treated with CFA (𝑁 = 9), and from untreated rats (𝑁 = 9).
3.1. Hepatic Expression of MT I+II Proteins in EAE-Resistant
and EAE-Prone Rats. The data have shown that the EAE-
prone DA rats react on immunization with BBH+CFA with a
significantly greater increase of hepatic MT I/II proteins than
EAE-resistant AO rats (Figures 1(a) and 1(b); 𝑃 < 0.001).
However, the content of MTs in intact livers of AO rats
was 3 times greater than that in DA rats, pointing to high
constitutive expression of these metal-binding proteins. As
shown by immunohistochemistry (Figure 1(c)), the immu-
nizedDA expressed a higher cytoplasmic and nuclearMT I/II
immunoreactivity in hepatocytes than AO rats.
3.2. Hepatic Expression of Glycoprotein gp96 in EAE-Resistant
and EAE-Prone Rats. The expression of ER-resident HSP-
gp96 protein significantly arose only in DA rats, immunized
with BBH+CFA (Figures 2(a) and 2(b)). The values were
significantly greater that those found in DA rats treated with
CFA, as well as than those found in identically treatedAO rats
(𝑃 < 0.001). Constitutive expression of gp96 protein in intact
livers of DA and AO rats was, however, of similar intensity
(Figure 2(b)). High hepatic upregulation of gp96 protein
in DA rats was also confirmed by immunohistochemistry,
showing prominent cytoplasmic gp96 immunoreactivity in
numerous hepatocytes (Figure 2(c)).
3.3. Hepatic Expression of IL-6 in EAE-Resistant and EAE-
Prone Rats. Similarly, in the livers of EAE-prone DA rats we
found a high upregulation of hepatic IL-6 protein during the
first attack of disease. Its values in livers of immunized DA
rats were significantly higher than those in DA rats treated by
CFA, as well as than those in EAE-resistant AO rats (Figures
3(a) and 3(b); 𝑃 < 0.001). However, resembling the findings
for MT I/II, in the livers of intact AO rats the expression of
IL-6 was four times higher than that in intact DA rats.
3.4. Hepatic Expression of TGF-𝛽 in EAE-Resistant and EAE-
Prone Rats. Hepatic expression of TGF-𝛽 was found to be
similar to that of MT I/II and IL-6. Its values became
markedly upregulated during the first attack of disease only
in DA rats (Figures 4(a) and 4(b); 𝑃 < 0.001). Besides, the
constitutive expression of TGF-𝛽 in livers of intact AO rats
was 2 times greater than that in DA rats (Figure 4(b)).
4. Discussion
Using an animal model, which in DA rats induces the clinical
symptoms of disease that resemble to relapsing-remitting
form of MS in humans, we show herein that hepatic IL-
6, TGF-𝛽, MTs, and ER-resident HSP-gp96 have a high
regulatory effect on inflammation and disturbed immune
mechanisms that occur during an autoimmune response.
Besides, the data imply that the susceptibility to EAEmight be
in association with the constitutive expression of hepatic MT
I/II, which are the essential cytoprotective proteins involved
in the regulation of different types of injuries. The cellular
and molecular mechanisms remain to be elucidated, but
the hypothesis is consistent with the well-known function
of the liver in controlling acute phase response [25] and
both immunity and tolerance [17, 26, 27]. In this context,
it has been repeatedly shown that the liver is characterized
by a specific hepatic microenvironment, created by gluco-
corticoids (GCs), local cytokines [5], and the unique hepatic
APC populations, which results in induction of the antigen-
specific peripheral tolerance rather than in induction of T-
cell immunity [17, 21]. In addition, it is known that, during
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Figure 1: Expression of MT I+II proteins in the livers of EAE-prone DA and EAE-resistant AO rats. (a) Representative western blots indicate
the MT I/II protein (∼14 kD; range 10–15 kD) detected by anti-MT MoAbs. The liver samples were obtained from intact rats and from rats
treated by bovine brain homogenate (BBH) and complete Freund’s adjuvant (CFA) or by CFA at the time of first attack in EAE-prone rats
(day 12). As a loading control the blots of 𝛽-actin protein (37–50 kD) are shown. (b) Relative protein expression is shown as AO/DA ratio
(intact liver) and as the percent of control (liver in EAE). All band densities were normalized corresponding to 𝛽-actin. Analyses were
made in tissue samples, prepared as a pool from 3 rats in three independent experiments. Data represent mean ± SE. (c) Representative
immunohistochemical staining of MT I/II proteins in paraffin-embedded sections of the liver tissue in DA and AO rats after treatment with
BBH+CFA or CFA. The results are representative findings of 3 rats.
an immune response, a wide variety of mediators, includ-
ing cytokines, growth factors, and hormones, must control
also the concomitant liver injury, inflammation, and repair
activating in different populations of liver cells (hepatocytes,
stellate cells, Kupffer cells, sinusoidal endothelial cells, and
lymphocytes) and various downstream signaling pathways.
The response depends on interactions of various mediators,
on the activation of individual Janus kinase (JAK)-signal
transducer and activator of transcription (STAT) pathways,
on interplay between the STAT1 and STAT3 activation, and on
subsequent activation of cytokine-induced negative feedback
loop that terminates JAK-STAT signaling by activation of
suppressors of cytokine signaling, SH2-containing phos-
phatases, and protein inhibitors of activated STATs. Owing
to this, the activation of various STATs might give anti- or
proinflammatory signals, depending on the STATs activated,
on the cell types in which the STATs are activated, and on
the type of liver disease or liver injury that has been studied
(reviewed by [28]).
In this regard, it has been shown that IL-22, IL-6, and IL-
6 family of cytokines led in hepatocytes and myeloid cells
to STAT3 activation, which acts as an anti-inflammatory
signal that suppress liver inflammation. In contrast, the
activation of STAT3 in T cells may even promote liver
inflammation, since it leads to the upregulation of the ROR𝛾t
and ROR𝛼 transcription factors that promote differentiation
of T cells towards a Th17 phenotype, contributing to the IL-
17 production. Moreover, the latter is highly influenced by
balance of IL-6 and TGF-𝛽, since IL-6 may inhibit TGF-
𝛽 induced differentiation of immunosuppressive Treg and
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Figure 2: Expression of gp96 in the livers of EAE-prone DA and EAE-resistant AO rats. (a) Representative western blots indicate the
gp96/GRP94 protein (∼200 kD; range 150–200 kD), detected by MoAb to Grp94/gp96 (clone 9G10) under a nonreducing condition in SDS-
PAGE. Liver samples were obtained from intact rats and from rats treated by bovine brain homogenate (BBH) and complete Freund’s adjuvant
(CFA) or by CFA at the time of first attack in EAE-prone rats (day 12). As a loading control the blots of 𝛽-actin protein (37–50 kD) are shown.
(b) Relative protein expression is shown as AO/DA ratio (intact liver) and as the percent of control (liver in EAE). All band densities were
normalized corresponding to𝛽-actin. Analyses weremade in tissue samples, prepared as a pool from 3 rats in three independent experiments.
Data representmean ± SE. (c) Representative immunohistochemical staining of gp96 protein in paraffin-embedded sections of the liver tissue
in DA and AO rats after treatment with BBH+CFA or CFA. The results are representative findings of 3 rats.
induce, in combination with TGF-𝛽, the development of
proinflammatoryTh17 cells from naıve T cells [29]. The issue
is covered by excellent reviews in this field [30–33], showing
that cytokines estimated in our study may have high impact
on self-tolerance and development of autoimmunity.
Consistent with this proposal in the present study we
show that IL-6 and TGF-𝛽 arose only in the livers of EAE-
prone DA rats during the first attack of EAE (Figures 3 and
4) implying that hepatic IL-6 and TGF-𝛽 contributed to the
generation of antigen-specific aggressive TH17 or TH1 cells.
However, in these considerations the time-course of events
should be taken into account, since IL-6 participates also in
processes that arrest the inflammatory response to infection
and tissue injury and ensure a good restoration of the affected
area. In this sense, it was shown that IL-6 stimulates the
transition from innate to acquired immunity [34], acting as a
factor that limits the entry of neutrophils into the affected area
and induces their elimination by apoptosis and as a factor that
stimulates the entry of monocytes and enables the survival of
T cells controlling the expression of several chemokines and
cytokines and adhesion molecules of the vascular endothe-
lium (reviewed by [35]). Furthermore, inducing in the liver
the synthesis of type II acute phase proteins (fibrinogen,
haptoglobin (human), 𝛼1-antichymotrypsin, 𝛼1-antitrypsin,
and 𝛼2-macroglobulin) IL-6 may limit the proteolytic and/or
fibrogenic activity and tissue damage [25, 36]. In addi-
tion, IL-6 and other proinflammatory cytokines, such as
TNF𝛼, IL-1𝛼, and IL-1ß, may lead to the activation of the
hypothalamic-pituitary-adrenal (HPA) axis feedback circuit,
which increases the levels of endogenous glucocorticoids
(GCs), as the immunosuppressive end product of this path-
way [5, 6]. Besides, it should be emphasized that IL-6 is a
critical cytokine, which induces the transcription of MT I/II
both in the liver [37–39] and in the brain [35, 40], leading
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Figure 3: Expression of IL-6 in the livers of EAE-prone DA and EAE-resistant AO rats. (a) Representative western blots indicate the IL-6
protein (∼25 kD; range 20–25 kD), detected by mouse anti-rat antibody to IL-6. The liver samples were obtained from intact rats and from
rats treated by bovine brain homogenate (BBH) and complete Freund’s adjuvant (CFA) or by CFA at the time of first attack in EAE-prone
rats (day 12). As a loading control the blots of 𝛽-actin protein (37–50 kD) are shown. (b) Relative protein expression is shown as AO/DA ratio
(intact liver) and as the percent of control (liver in EAE). All band densities were normalized corresponding to 𝛽-actin. Analyses were made
in tissue samples, prepared as a pool from 3 rats in three independent experiments. Data represent mean ± SE.
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Figure 4: Expression of TGF-𝛽 in the livers of EAE-proneDA and EAE-resistant AO rats. (a) Representative western blots indicate the TGF-𝛽
protein (∼44 kD; range 35–55 kD), detected by mouse anti-rat antibody to IL-6 in the liver samples obtained from intact rats and rats treated
by bovine brain homogenate (BBH) and complete Freund’s adjuvant (CFA) or by CFA at the time of first attack in EAE-prone rats (day 12). As
a loading control the blots of 𝛽-actin protein (37–50 kD) are shown. (b) Relative protein expression is shown as AO/DA ratio (intact liver) and
as the percent of control (liver in EAE). All band densities were normalized corresponding to 𝛽-actin. Analyses were made in tissue samples,
prepared as a pool from 3 rats in three independent experiments. Data represent mean ± SE.
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eventually to the marked cytoprotective and neuroprotective
outcome, as it has been shown in various physiological
conditions [16, 41] and in EAE [42], MS, [43] and other types
of brain injury [13, 44, 45]. Accordingly, IL-6 deficiency may
increase the oxidative stress during CNS inflammation [40].
However, since the overproduction of IL-6 and abnormalities
in IL-6 signal transduction might be causative factors in
several autoimmune disorders, the IL-6 blockade might be
an effective approach in their treatment (reviewed by [33]).
In line with this evidence, it was shown that anti-IL-6R
antibodies, administered immediately after immunization
of mice with myelin oligodendrocyte glycoprotein (MOG)
peptide, were able to suppress the occurrence of EAE, leading
to elimination of the Th17 cells in the draining lymph nodes
and in the spinal cord [46].
Supporting the current knowledge about the prominent
regulatory functions of metallothioneins in pathogenesis of
EAE and other types of brain injuries [35, 45, 47], we
previously reported that the expression metallothioneins I/II
might be induced in both EAE-prone and EAE-resistant
strain of rats, even in the presymptomatic phase of CR-EAE
(on the seventh postimmunization day) in cells that form
blood-brain and blood-cerebrospinal fluid barriers, in the
cerebellar parenchyma and hippocampal dentate gyri, as well
as in the liver of rats [12]. However, on the 12th postim-
munization day, the levels of hepatic IL-6, TGF-beta, MTs,
and gp96 were significantly greater in DA than in AO rats,
implying that AO rats might better control the autoimmune
reaction [12]. Moreover, since in AO rats we noticed an early
upregulation of TGF-𝛽on several hepatic structures (vascular
endothelium, Kupffer cells, and hepatocytes), we speculated
that specific hepatic microenvironment might contribute to
the faster recovery of these rats from EAE [12]. The new
data from current study, also revealed that AO rats have
greater basal levels of TGF-𝛽, IL-6, and MT I/II (Figures
4, 3, and 1), implying that the susceptibility in AO and
DA rats might depend not only on MHC haplotype, but
also on some epigenetic traits that might be responsible for
immunomodulation [48].
Our data do not permit further discussion in this direc-
tion since the susceptibility to EAE is a polygenic trait, in
which small differences in the expression or activities of
different gene products combine to determine the initiation
of disease [1–3]. In most strains the response is governed
by the MHC class II gene products and by the T-cell
receptor (TCR) repertoire, which recognize the dominant
encephalitogenic epitope, but the susceptibility may depend
also on genetic traits responsible for interindividual differ-
ences in metabolism and sensitivity to various pathogens
and endogenous factors. In addition, it often correlates
with dominant type-1 (cell-mediated) or type-2 (humoral
or antibody-mediated) immunity of the strain, which are
highly influenced by neuroimmune interactions and signal-
ing within the hypothalamic-pituitary-adrenal axis [49], as
well as by regulatory mechanisms that include the generation
of cells and cytokines with suppressive activity and activation
of the pathways that ensure the apoptotic elimination of
autoaggressive T-cell clones [5, 6].
As a small segment of this complex network, we show
herein that in regulation of susceptibility to EAE participate
also hepaticMTs, owing to their important functions inmetal
ion homeostasis and redox control and in protection against
heavy metals, DNA damages, stress, and inflammation [16,
41, 50, 51]. Moreover, owing to their ability to control Zn-
dependent transcription factors, protein synthesis, cellular
energy, levels andmetabolism, they are also critically involved
in cell growth and multiplication [37, 52], as well as in the
maintenance of neuroimmune homeostasis and processes of
apoptosis [51]. Accordingly, we can speculate that high con-
stitutiveMT expression inAO rats and high inducible hepatic
MTs inDA rats contributed to lower susceptibility to EAE and
to the restrain of autoimmune and inflammatory response.
It is likely that the underlining mechanisms are different in
quiescent and injured liver tissue, but at the present they
remain elusive. However, reflecting the antioxidative activity
of MT I/II during EAE, we previously reported that in DA
rats tissue content of free zinc ions increased at the sites
of MTs induction [24] as well as that during the second
attack of CR-EAE (on the 22nd postimmunization day) the
hepatic expression of MT I/II was accompanied by high
accumulation of Zn and Cu in the liver [23]. Moreover, linear
regression analysis made in the present study revealed that
in the intact liver of AO rats the tissue levels of MTs were in
high positive correlation with tissue levels of IL-6 (𝑟 = 0. 87).
In contrast, in immunized rats of both strains hepatic IL-6
(detected on 12th day after immunization with BBH+CFA)
was in a high negative correlation with the hepatic gp96 (𝑟 =
0.97). However, these preliminary data need to be confirmed
(not shown).
Furthermore, in this study we show that during EAE
markedly changes also the hepatic expression of ER-resident
HSP-gp96 (Figure 2), confirming the contribution of endoge-
nousDAMP signals in development of autoimmune response
[4, 19]. Owing to its chaperon role in the unfolded pro-
tein response (UPR) [53–55] and ER-associated degradation
(ERAD) [56] there is a possibility that hepatic gp96 during
EAE was involved in the processes that regulate the proper
folding and assembly of newly synthesized secretory and
membrane proteins and in those that prevent the aggregation
of unfolded and incompletely folded proteins in the ER.
Besides, owing to its ability to actively chaperon MHC class
I-restricted epitopes into the cross-presentation pathway of
professional antigen-presenting cells (APC) and induce the
activation and maturation of these cells [19, 57], we can also
speculate that gp96 actively contributed to the induction
antigen-specific immunity after the immunizationwith BBH-
CFA. The hypothesis is confirmed by numerous reports
pointing to a high upregulation of HSP in CNS during the
exposure of cells to various kinds of stress and infection [58,
59], as well as in MS [60], EAE [61], and other neurological
diseases [18], often called “chaperonopathies.”
Direct effects of gp96 on EAE is also confirmed by finding
that immunization of mice with HSP+peptide complexes
might elicit CD8+ and CD4+ T-cell responses specific to
the HSP-chaperoned antigenic peptides [19] as well as that
immunization with high doses of gp96 might prevent myelin
basic protein or proteolipid protein-induced autoimmune
8 Clinical and Developmental Immunology
encephalomyelitis in SJL mice by induction of suppressor
CD4+ population, showing that gp96 might induce both the
antigen-specific activation or suppression of cellular immune
responses [62].
Confirming that gp96 might be involved in proteostasis
and immune-related pathways, linked with the reparative
processes in the CNS, we recently reported that in DA rats
the constitutive gp96 expression, found in several neurons
and glial cells in the brain and spinal cord of intact animals,
significantly diminished during the attacks of CR-EAE as well
as that gp96 was upregulated during the remission phase of
CR-EAE disease in the oligodendrocytes, in the neurons of
the hippocampal area, and in the motoneurons of lumbar
spinal cord [22]. The finding points to the role of gp96
in immune mechanisms showing that gp96 may stimulate
the Treg cells in a dose dependent manner [63] as well as
that gp96 may regulate the generation of tolerogenic pDCs
[64] and participate in maintenance of tolerance in multiple
sclerosis [65].
We would like also to underline that in other animals
models with disturbance of morphostasis (liver regeneration,
stress, syngeneic pregnancy, treatment with peptidoglycan,
and autoimmune diabetes) [66, 67] the hepatic gp96 over-
expression often correlated with a high accumulation of
natural killer (NKT) cells, as well as with upregulation of
costimulatory molecule on APC and generation of Treg in
the liver and in the thymus, pointing to the general role of
ER chaperons in the maintenance of immune homeostasis
and morphostasis [66, 67]. Based on these lines of evidence
and current knowledge of immune functions of gp96 [20]
we can, therefore, speculate that hepatic gp96 during EAE
might affect the maturation of local dendritic cells and
their tolerogenic and cytokine induction potential, as well
as the functions of hepatic NKT cells, which recognize the
conserved stress-induced self-structures, rather than variable
foreign antigens [68]. However, although it was shown that
the liver-confined invariant NKT cells after activation by
alphaGalCer might suppress Th1-cytokine production and
foster the secretion of IL-10 from MOG35-55-specific T cells
[69], our data need further experiments in this direction.
Concluding, we would like to underline that the expres-
sion profile of MTs and gp96 in DA rats immunized with
BBH+CFA showed a large temporal and regional variability
[23], emphasizing their interactions with multiple control
pathways. In our experiments the MT I/II expression corre-
lated more with the peaks of clinical symptoms, in contrast
to gp96, which was found in remission phases, suggesting
that ER chaperones might be induced to ameliorate the
accumulation of misfolded proteins in the CNS and protect
neuronal cells against autoimmune attack. The importance
of time-course evaluation of the data is emphasized also in
the present study, which imply that EAE-resistant rats may
more efficiently restrain the autoimmune response, owing to
greater constitutive expression of hepatic MT I/II and IL-6
(Figures 1 and 3) and owing to an early upregulation of TGF-
𝛽 in the liver [12].
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